SCHEMBL23717786

SCHEMBL23717786

CCCCCCC[C@@H](CCCCC)c1c(OC)ncnc1OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
SLC2A1 P11166 1/20 0.33
ADA P00813 5/20 0.33
KDR P35968 1/20 0.33
NR1I2 O75469 1/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
PDE2A O00408 2/20 0.32
CYP3A4 P08684 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725527 0.93 NPC1 (0.37) CYP1A2SMN1; SMN2NPC1CYP2C9CYP2C19
SCHEMBL21725530 0.82 NPC1 (0.33) CYP1A2SMN1; SMN2NPC1CYP2C9CYP2C19
SCHEMBL20621620 0.75 NR1I2 (0.34) CYP1A2SMN1; SMN2ADAKDRNR1I2
SCHEMBL21143476 0.75 NR1I2 (0.34) CYP1A2SMN1; SMN2ADAKDRNR1I2
SCHEMBL22400168 0.73 PDPK1 (0.34) CYP1A2SMN1; SMN2NPC1CYP2C9CYP2C19
SCHEMBL20222983 0.71 CRHR1 (0.36) SLC2A1FAAH
SCHEMBL25065157 0.71 HTR2A (0.33) CYP2C19SLC2A1ADAKDR
SCHEMBL20738909 0.71 PPARA (0.41) FAAHMGLLCYP3A4
SCHEMBL24366912 0.69 HPGD (0.36) SMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL24608668 0.69 PPARG (0.38) NR1I2FAAHMGLLCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R CYP1A2 1383/4885SMN1; SMN2 2938/4885NPC1 1729/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R CYP1A2 1383/4885SMN1; SMN2 2938/4885NPC1 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.